News

Atossa Therapeutics Q3 2024 Financial Highlights and Updates

Atossa Therapeutics Q3 2024 Financial Highlights and Updates

Atossa Therapeutics Shares Positive Q3 2024 Results

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a pioneering clinical-stage biopharmaceutical company focusing on breast cancer innovations, recently reported its financial achievements for the third quarter of 2024. This report highlights a notable cash position of $74.8 million and significant milestones in clinical trial progress.

Clinical Advancements in Breast Cancer Treatment

In Q3 2024, Atossa generated positive topline findings from its KARISMA-Endoxifen Phase 2 study at the Karolinska Institute in Sweden. Conducted among premenopausal women with mammographic breast density (MBD), the trial validated that low doses of (Z)-endoxifen effectively diminished breast density, a known risk factor for breast cancer, by up to 26.5%.

Details of Recent Clinical Trials

KARISMA-Endoxifen Study

The results from the KARISMA study demonstrated a significant 19.3% reduction in breast density with the 1 mg treatment and a substantial 26.5% decrease with the 2 mg dosage over six months, contrasting sharply with the placebo group. Importantly, participants reported minimal side effects, reinforcing the treatment's potential as a preventative option.

I-SPY 2 EOP Trial

Further bolstered by preliminary findings from the I-SPY 2 Endocrine Optimization Pilot (EOP) trial, Atossa revealed that 95% of patients receiving (Z)-endoxifen completed over 75% of their planned treatments. This trial showcased a rapid 69% reduction in Ki-67, a critical biomarker for breast cancer proliferation, alongside a 30.4% decrease in tumor volume within three weeks of treatment.

New Patents and Collaborations

Patent Granted for (Z)-Endoxifen

Atossa has been granted a U.S. Patent covering specific formulations of (Z)-endoxifen, enhancing its protection and commercial prospects for this crucial drug. This patent aims to cover compositions in both free base and salt forms with enteric materials. Furthermore, the company announced the first patient dosing in a trial exploring the combination of (Z)-endoxifen and abemaciclib (VERZENIO) for treating women with high-risk breast cancer.

Leadership Enhancements

In addition to trial advancements, Atossa recently appointed Michael Parks as Vice President of Investor and Public Relations, tapping his extensive experience in investor communications. Additionally, Claudia Lopez, DVM, MSc, was brought on as Vice President of Clinical Product Development, substantially strengthening Atossa's leadership team.

Financial Overview

For the fiscal quarter ended September 30, 2024, Atossa's operational costs totaled $6.4 million, reflecting notable efficiencies compared to $7.5 million for the same quarter in 2023. This decrease in expenses is attributable to reductions in both R&D and general administrative costs.

Research and Development Expenses

Research and development expenses decreased due to lowered spending on (Z)-endoxifen trials, with clinical trial costs dropping significantly. Compensation expenses for R&D also saw a reduction as a result of decreased stock-based compensation, which was influenced by lower average stock option values.

General and Administrative Expenses

Within general and administrative expenses, Atossa reported a decrease primarily due to strategic cuts in cash compensation, fees associated with legal activities, and insurance premiums. However, a notable increase was observed in professional fees relating to legal and investor relations activities.

Conclusion and Future Outlook

Atossa Therapeutics continues to innovate and lead in the development of preventative and therapeutic options for breast cancer. The positive outcomes from the recent clinical studies and the strategic appointments within the company position it well for future success. With a solid financial grounding, Atossa is prepared to advance its properties further and meet the growing needs within the oncology sector.

Frequently Asked Questions

What were Atossa Therapeutics' recent clinical trial results?

Atossa announced significant reductions in mammographic breast density from its KARISMA-Endoxifen Phase 2 study, expanding its possibilities in breast cancer prevention.

What is (Z)-endoxifen and its role?

(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator being developed to help treat and prevent breast cancer, showing promising clinical trial results.

Who were the recent appointments at Atossa Therapeutics?

Michael Parks was named Vice President of Investor and Public Relations, and Claudia Lopez was appointed Vice President of Clinical Product Development, strengthening company leadership.

How has Atossa's financial performance been recently?

Atossa ended Q3 2024 with $74.8 million in cash and no debt, an improvement from the previous year.

What strategies is Atossa implementing for future growth?

Atossa aims to leverage its positive clinical trial results and enhance its product pipeline while maintaining firm financial strategies to boost growth.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 129

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 112

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 111

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 131

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 75

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 199

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Trip.com Sets December 1 Date for Third-Quarter Results

Updated Category News Views 122

December’s first after-hours session will put Trip.com Group back under the market’s microscope, whether anybody is ready or not. The company says it will report results for the three months ended September 30, 2026 after the U.S. market closes on Tuesday, December 1. That is the whole hard-news payload for now: a reporting date, a call time, and no numbers to get...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 157

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Tools Revolutionizing Family Medicine Screening

Updated Category News Views 120

Innovative AI Tools Revolutionizing Family Medicine Screening Recent studies illustrate the integration of AI in detecting health issues within family medicine Research published in Annals of Family Medicine delves into how artificial intelligence and digital applications such as tablets are enhancing the detection of significant health conditions like dementia, heart...

Continue Reading
Infortar's Strategic Share Buyback on Nasdaq Tallinn

Updated Category News Views 168

Infortar's Share Buyback Strategy Aktsiaselts Infortar has taken a strategic step by acquiring its own shares on the Nasdaq Tallinn Stock Exchange during the early November period. This initiative reflects the company’s commitment to enhancing shareholder value and maintaining a robust market presence. Details of the Share Acquisition During the acquisition phase from...

Continue Reading
Garmin Ltd. Announces Upcoming Earnings Call for Investors

Updated Category News Views 41

Garmin Ltd. Schedules Third Quarter Earnings Call Garmin Ltd. (NYSE: GRMN) is preparing for its third quarter earnings conference call, inviting all shareholders and interested parties to join. The call is an important event where executives will discuss recent business performance and future strategies. It will take place on a Wednesday at 10:30 a.m. EDT, coinciding with...

Continue Reading
BMC Medical Co., Ltd. Celebrates New France Office Opening

Updated Category News Views 152

Exciting Times for BMC Medical Co., Ltd. with New Office Opening BMC Medical Co., Ltd. has recently marked an important milestone with the launch of its new office. This occasion not only establishes a foothold in the local area but also demonstrates the company's commitment to improving healthcare services throughout Europe. A Grand Opening Ceremony Celebrating Growth...

Continue Reading
TGH Burn Center Enhances Care Through TECO Partnership

Updated Category News Views 202

Transforming Burn Care at TGH Burn Center The TGH Burn Center, previously known as Tampa General Hospital's Burn Center, has entered into an exciting partnership with TECO that aims to significantly enhance patient care. This collaboration focuses on innovative treatment and state-of-the-art technology to ensure that those suffering from burn injuries receive the best...

Continue Reading